Brolucizumab is an anti-VEGF-A antibody fragment for cancer research
**Background** Vascular endothelial growth factor A (VEGF-A) is a critical mediator of angiogenesis, the process by which new blood vessels form from pre-existing ones. Overexpression of VEGF-A is frequently observed…